首页> 外文期刊>Microbiology and Immunology >Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome
【24h】

Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome

机译:通过针对病毒基因组NS3和NS5B区的RNA干扰抑制丙型肝炎病毒复制子

获取原文
获取原文并翻译 | 示例
           

摘要

RNA interference (RNAi) is a phenomenon in which small interfering RNA (siRNA), an RNA duplex 21 to 23 nucleotides (nt) long, or short hairpin RNA (shRNA) resembling siRNA, mediates degradation of the target RNA molecule in a sequence-specific manner. RNAi is now expected to be a useful therapeutic strategy for hepatitis C virus (HCV) infection. In the present study we compared the efficacy of a number of shRNAs directed against different target regions of the HCV genome, such as 5'-untranslated region (5'UTR) (nt 286 to 304), Core (nt 371 to 389), NS3-1 (nt 2052 to 2060), NS3-2 (nt 2104 to 2122), and NS5B (nt 7326 to 7344), all of which except for NS5B are conserved among most, if not all, HCV subtype 1b (HCV-1b) isolates in Japan. We utilized two methods to express shRNAs, one utilizing an expression plasmid (pAVU6+27) and the other utilizing a recombinant lentivirus harboring the pAVU6+27-derived expression cassette. Although 5'UTR has been considered to be the most suitable region for therapeutic siRNA and/or shRNA because of its extremely high degree of sequence conservation, we observed only a faint suppression of an HCV subgenomic replicon by shRNA against 5'UTR. In both plasmid- and lentivirus-mediated expression systems, shRNAs against NS3-1 and NS5B suppressed most efficiently the replication of the HCV replicon without suppressing host cellular gene expression. Synthetic siRNA against NS3-1 also inhibited replication of the HCV replicon in a dose-dependent manner. Taken together, the present results imply the possibility that the recombinant lentivirus expressing shRNA against NS3-1 would be a useful tool to inhibit HCV-1b infection.
机译:RNA干扰(RNAi)是一种现象,其中小干扰RNA(siRNA),长21至23个核苷酸(nt)的RNA双链体或类似于siRNA的短发夹RNA(shRNA),可在序列中介导目标RNA分子的降解-具体的方式。现在预期RNAi将成为治疗丙型肝炎病毒(HCV)的有用治疗策略。在本研究中,我们比较了许多针对HCV基因组不同靶区域的shRNA的功效,例如5'非翻译区(5'UTR)(nt 286至304),Core(nt 371至389), NS3-1(nt 2052至2060),NS3-2(nt 2104至2122)和NS5B(nt 7326至7344),除了NS5B以外,其他所有(即使不是全部)HCV亚型1b(HCV- 1b)日本分离株。我们利用两种方法表达shRNA,一种利用表达质粒(pAVU6 + 27),另一种利用携带pAVU6 + 27衍生表达盒的重组慢病毒。尽管5'UTR由于其极高的序列保守性而被认为是最适合治疗性siRNA和/或shRNA的区域,但我们观察到,shRNA仅针对5'UTR轻微抑制了HCV亚基因组复制子。在质粒和慢病毒介导的表达系统中,针对NS3-1和NS5B的shRNA均能最有效地抑制HCV复制子的复制,而不会抑制宿主细胞基因的表达。抗NS3-1的合成siRNA也以剂量依赖的方式抑制HCV复制子的复制。综上所述,本发明结果暗示了表达针对NS3-1的shRNA的重组慢病毒将是抑制HCV-1b感染的有用工具的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号